OnKure Therapeutics Inc. Class A Common Stock (OKUR)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach OnKure as a Graham-style balance-sheet case, not a Buffett-style compounder. It is a clinical-stage biopharmaceutical company with 45 employees and no revenue, developing OKI-219, a selective PI3K alpha inhibitor in Phase 1 for solid tumors including breast cancer. The financial record is that of a cash-consuming enterprise: net loss was $35.3 million in FY2023, $52.7 million in FY2024, and $59.5 million in FY2025. More recently, fiscal Q3 2025 lost $14.7 million, fiscal Q4 2025 lost $13.5 million, fiscal Q1 2026 lost $15.2 million, and fiscal Q2 2026 lost $15.3 million. Trailing free cash flow was -$47.9 million, a -50.4% FCF yield on the $95 million market cap, per FairStock calculations. The balance sheet has little debt, with D/E of 0.01, and FairStock's Altman Z-Score is 7.10, but its Piotroski F-Score is 1/9, showing weak fundamental momentum. At the 2026-10-13 close of $2.35, FairStock shows P/B of 0.55 and P/E of -0.77 on EPS of -$3.03. A sub-book price can attract a bargain hunter, yet the assets are largely being spent on trials, so value erodes with each quarter of burn. The competitive moat is not yet visible; value rests on intellectual property and clinical data, which are binary and unproven. Growth is not revenue growth but progress through Phase 1. The Lynch category is none because it lost money in each of the last four years. This is speculative, not a durable franchise.

In plain English: OnKure Therapeutics is a small healthcare company trying to develop a new cancer medicine, and it is still in early testing. It has no product sales and is losing money, so the business looks financially weak, though the stock price is low compared with the company's accounting value. Because the medicine is unproven, the price may look cheap on paper but the real outcome depends on test results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer